Diabetes News and Research

Latest Diabetes News and Research

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

FDA approves key testing phase for artificial pancreas

A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.

19 Mar 2012

New medical education portal - Lipoprotein Perspectives - launched

LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical tests using nuclear magnetic resonance (NMR) technology, announced the launch of Lipoprotein Perspectives - a medical education portal featuring experts in clinical and preventive cardiology, endocrinology, and lipidology - at www.lipoprotein.org.

19 Mar 2012

Software tool accurately estimates risk of heart disease

University of Granada researchers have developed a software tool that makes an accurate estimation of the risk that a person has to suffer a heart disease. In addition, this software tool allows the performance of massive risk estimations, i.e. it helps estimating the risk that a specific population group has of suffering a heart condition. The researchers employed a sample including 3 000 patients.

19 Mar 2012

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.

19 Mar 2012

Gender gap in medication management

There is a wide gender divide when it comes to how men and women are prescribed and adhere to their medications. According to a new study, while women use more prescription drugs than men, they are less likely to be prescribed drugs according to clinical guidelines and are not as good about adhering to the medications they are prescribed.

19 Mar 2012

Largest ever academic-industry research project to find new drugs for ASD

An international consortium of scientists, led by Roche, King's College London, and Autism Speaks, is collaborating on one of the largest ever academic-industry research projects to find new methods for the development of drugs for autism spectrum disorder.

From CSL Ltd 19 Mar 2012

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started.

19 Mar 2012

New software tool can accurately estimate risk of heart disease

19 Mar 2012

EU-funded 'afresh'-project looks at food and physical activity

Food and physical activity are looked at together in the EU-funded "afresh"-project. Eight regional clusters - strong in food and/or health - currently are setting up their joint future agenda aiming at the prevention of diet-and activity related deseases like obesity, diabetes, cardiovasculaire deseases, osteoporose, etc.

19 Mar 2012

Researchers show how errant form of LYP can disrupt the immune system

Autoimmune diseases, such as Type I diabetes and rheumatoid arthritis, are caused by an immune system gone haywire, where the body's defense system assaults and destroys healthy tissues. A mutant form of a protein called LYP has been implicated in multiple autoimmune diseases, but the precise molecular pathway involved has been unknown.

19 Mar 2012

Study reveals how Bdnf gene mutation contributes to severe obesity

Researchers at Georgetown University Medical Center have revealed how a mutation in a single gene is responsible for the inability of neurons to effectively pass along appetite suppressing signals from the body to the right place in the brain. What results is obesity caused by a voracious appetite.

19 Mar 2012

Pfizer supports First World Congress on Healthy and Active Ageing

As an official partner of the First World Congress on Healthy Ageing, Pfizer reaffirms the company's commitment to promote healthy and active ageing at all stages of life as a basis for enhanced productivity in the Asia Pacific. Pfizer will lead a luncheon symposium today focused on the relationship between health and economic sustainability and the resulting challenges and opportunities of shifting demographics across the region.

19 Mar 2012

3 million Australians to develop diabetes by 2025

According to the latest figures, one in three of today's young Australians will go on to develop diabetes. A new assessment of national health data released by Diabetes Australia today shows 1.5 million Australians currently have diabetes. It says the diabetes rate is likely to at least double in Australia over the next decade, and predicts 3 million people will have type 2 diabetes by 2025.

18 Mar 2012

Feds begin funding cuts to Texas Women's Health Program

Federal officials said they would begin to phase out their 90-percent portion of the Texas Women's Health Program as they had promised to do after Texas lawmakers banned Planned Parenthood from the program. CMS officials said the reductions would be gradual.

17 Mar 2012

Sanofi enters definitive agreement to acquire Pluromed

Sanofi and Pluromed Inc. announced today that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts.

17 Mar 2012

WASM, Philips partner to raise awareness of sleep disorders

Royal Philips Electronics will join with the World Association of Sleep Medicine (WASM) as an official sponsor of World Sleep Day 2012, held on Friday, March 16. This year's theme– 'Breathe Easily, Sleep Well' – centers on raising awareness of sleep disorders that affect a person's breathing, such as obstructive sleep apnea.

17 Mar 2012

HGF/C-MET signaling pathway plays a key role in gestational diabetes development

Researchers at the University of Pittsburgh School of Medicine have identified a cell-signaling pathway that plays a key role in increasing insulin secretion during pregnancy and, when blocked, leads to the development of gestational diabetes.

17 Mar 2012

Einstein members celebrate 2012 Match Day

Members of Albert Einstein College of Medicine of Yeshiva University's graduating class celebrated another strong year for residency placements in competitive specialties and prestigious programs at this year's Match Day. Representing the culmination of their medical school education, Match Day marked the transition of Einstein's class of 2012 into the post-graduate phase of their training - when they will practice medicine in a clinical setting under the supervision of fully licensed physicians.

17 Mar 2012

Echo total revenues increase to $447,000 for fiscal year 2011

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced financial results for the year ended December 31, 2011.

17 Mar 2012